BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59:1293-1302. [PMID: 24122848 DOI: 10.1002/hep.26892] [Cited by in Crossref: 194] [Cited by in F6Publishing: 169] [Article Influence: 27.7] [Reference Citation Analysis]
Number Citing Articles
1 Schultheiss HP, Fairweather D, Caforio ALP, Escher F, Hershberger RE, Lipshultz SE, Liu PP, Matsumori A, Mazzanti A, McMurray J, Priori SG. Dilated cardiomyopathy. Nat Rev Dis Primers 2019;5:32. [PMID: 31073128 DOI: 10.1038/s41572-019-0084-1] [Cited by in Crossref: 83] [Cited by in F6Publishing: 65] [Article Influence: 41.5] [Reference Citation Analysis]
2 Fabrizi F, Donato FM, Messa P. Hepatitis C and Its Metabolic Complications in Kidney Disease. Ann Hepatol. 2017;16:851-861. [PMID: 29055921 DOI: 10.5604/01.3001.0010.5275] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
3 Lin SP, Wu CY, Wang CB, Li TC, Ko NY, Shi ZY. Risk of diabetes mellitus in HIV-infected patients receiving highly active antiretroviral therapy: A nationwide population-based study. Medicine (Baltimore) 2018;97:e12268. [PMID: 30200166 DOI: 10.1097/MD.0000000000012268] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
4 Fabrizi F, Cerutti R, Dixit V, Messa P. The impact of antiviral therapy for HCV on kidney disease: a systematic review and meta-analysis. Nefrologia (Engl Ed) 2020;40:299-310. [PMID: 31813592 DOI: 10.1016/j.nefro.2019.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Ladino M, Pedraza F, Roth D. Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease. World J Hepatol. 2017;9:833-839. [PMID: 28740594 DOI: 10.4254/wjh.v9.i19.833] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Khan MU, Mahmoud MI, Butt AA. Hepatitis c virus and chronic kidney disease. Expert Rev Gastroenterol Hepatol 2020;14:579-90. [PMID: 32613874 DOI: 10.1080/17474124.2020.1776111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Henson JB, Sise ME. The association of hepatitis C infection with the onset of CKD and progression into ESRD. Semin Dial 2019;32:108-18. [PMID: 30496620 DOI: 10.1111/sdi.12759] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
8 Chen YC, Hwang SJ, Li CY, Wu CP, Lin LC. A Taiwanese Nationwide Cohort Study Shows Interferon-Based Therapy for Chronic Hepatitis C Reduces the Risk of Chronic Kidney Disease. Medicine (Baltimore). 2015;94:e1334. [PMID: 26266379 DOI: 10.1097/md.0000000000001334] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
9 Kinoshita C, Nagano T, Seki N, Tomita Y, Sugita T, Aida Y, Itagaki M, Satoh K, Sutoh S, Abe H, Tsubota A, Aizawa Y. Hepatitis C virus G1b infection decreases the number of small low-density lipoprotein particles. World J Gastroenterol 2016;22:6716-25. [PMID: 27547014 DOI: 10.3748/wjg.v22.i29.6716] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Li J, Gordon SC, Rupp LB, Zhang T, Trudeau S, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Schmidt MA, Daida YG, Lu M;  CHeCS Investigators. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes. Aliment Pharmacol Ther. 2019;49:599-608. [PMID: 30650468 DOI: 10.1111/apt.15102] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
11 Sharma G, Raheja H, Das S. Hepatitis C virus: Enslavement of host factors. IUBMB Life 2018;70:41-9. [PMID: 29281185 DOI: 10.1002/iub.1702] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
12 Isnard Bagnis C, Cacoub P. Hepatitis C Therapy in Renal Patients: Who, How, When? Infect Dis Ther 2016;5:313-27. [PMID: 27388502 DOI: 10.1007/s40121-016-0116-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
13 Shiffman ML, Benhamou Y. Cure of HCV related liver disease. Liver Int 2015;35 Suppl 1:71-7. [PMID: 25529090 DOI: 10.1111/liv.12734] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
14 Tung CH, Lai NS, Li CY, Tsai SJ, Chen YC, Chen YC. Risk of rheumatoid arthritis in patients with hepatitis C virus infection receiving interferon-based therapy: a retrospective cohort study using the Taiwanese national claims database. BMJ Open 2018;8:e021747. [PMID: 30037875 DOI: 10.1136/bmjopen-2018-021747] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Fabrizi F, Messa P, Martin P. The Unravelled Link between Chronic Kidney Disease and Hepatitis C Infection. New Journal of Science 2014;2014:1-9. [DOI: 10.1155/2014/180203] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
16 Tada T, Kumada T, Toyoda H, Sone Y, Takeshima K, Ogawa S, Goto T, Wakahata A, Nakashima M, Nakamuta M, Tanaka J. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy. Aliment Pharmacol Ther. 2018;47:1012-1022. [PMID: 29424449 DOI: 10.1111/apt.14554] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 8.3] [Reference Citation Analysis]
17 Dusheiko G. The impact of antiviral therapy for hepatitis C on the quality of life: a perspective. Liver Int. 2017;37 Suppl 1:7-12. [PMID: 28052638 DOI: 10.1111/liv.13292] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
18 Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46 Suppl 5:S165-S173. [PMID: 25458776 DOI: 10.1016/j.dld.2014.10.005] [Cited by in Crossref: 163] [Cited by in F6Publishing: 144] [Article Influence: 23.3] [Reference Citation Analysis]
19 Beig J, Orr D, Harrison B, Gane E. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients. Liver Transpl 2018;24:1031-9. [PMID: 29577581 DOI: 10.1002/lt.25060] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
20 Shiffman ML, Gunn NT. Impact of hepatitis C virus therapy on metabolism and public health. Liver Int 2017;37 Suppl 1:13-8. [PMID: 28052632 DOI: 10.1111/liv.13282] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
21 Wen D, Du X, Dong JZ, Ma CS. Hepatitis C virus infection and risk of coronary artery disease: A meta-analysis. Eur J Intern Med 2019;63:69-73. [PMID: 31006509 DOI: 10.1016/j.ejim.2019.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Rogal SS, Yan P, Rimland D, Re VL, Al-rowais H, Fried L, Butt AA; The ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Group. Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES. Dig Dis Sci 2016;61:930-6. [DOI: 10.1007/s10620-015-3918-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
23 Goossens N, Negro F. Cardiovascular Manifestations of Hepatitis C Virus. Clin Liver Dis 2017;21:465-73. [PMID: 28689586 DOI: 10.1016/j.cld.2017.03.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
24 Lapumnuaypol K, Thongprayoon C, Wijarnpreecha K, Cheungpasitporn W. Impact of hepatitis C sustained viral response on cardiovascular diseases: a meta-analysis. Hosp Pract (1995). 2019;47:105-110. [PMID: 31018721 DOI: 10.1080/21548331.2019.1612066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Ribaldone DG, Sacco M, Saracco GM. The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. J Clin Med. 2020;9. [PMID: 32092892 DOI: 10.3390/jcm9020563] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
26 Lee YC, Hung SY, Wang HK, Lin CW, Wang HH, Chang MY, Sung JM, Chiou YY, Lin SH. Is there different risk of cancer among end-stage renal disease patients undergoing hemodialysis and peritoneal dialysis? Cancer Med 2018;7:485-98. [PMID: 29356425 DOI: 10.1002/cam4.1289] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
27 Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN)., Italian Association for the Study of the Liver (AISF)., Italian Society of Infectious and Tropical Disease (SIMIT)., Italian Society of Internal Medicine (SIMI). Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Infection 2019;47:141-68. [PMID: 30255389 DOI: 10.1007/s15010-018-1209-2] [Reference Citation Analysis]
28 Petta S. Hepatitis C virus and cardiovascular: A review. J Adv Res 2017;8:161-8. [PMID: 28149651 DOI: 10.1016/j.jare.2016.06.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
29 Colombo M, Strasser S, Moreno C, Abrao Ferreira P, Urbanek P, Fernández I, Abdurakmonov D, Streinu-Cercel A, Verheyen A, Iraqi W. Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program. J Hepatol. 2014;61:976-983. [PMID: 24946280 DOI: 10.1016/j.jhep.2014.06.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
30 Viganò M, Colombo M. Extrahepatic Manifestations of Hepatitis C Virus. Gastroenterol Clin North Am 2015;44:775-91. [PMID: 26600219 DOI: 10.1016/j.gtc.2015.07.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
31 Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxì A, Cammà C. Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. Gastroenterology. 2016;150:145-155.e4; quiz e15-16. [PMID: 26386298 DOI: 10.1053/j.gastro.2015.09.007] [Cited by in Crossref: 137] [Cited by in F6Publishing: 119] [Article Influence: 22.8] [Reference Citation Analysis]
32 Negro F. HCV causes systemic disorders that can be cured. Nat Rev Gastroenterol Hepatol 2014;11:77-8. [DOI: 10.1038/nrgastro.2013.222] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
33 van der Meer AJ. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:364-366. [PMID: 25601636 DOI: 10.1136/gutjnl-2014-308745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
34 Hsu Y, Muo C, Liu C, Tsai W, Hsu C, Sung F, Kao C. Hepatitis C virus infection increases the risk of developing peripheral arterial disease: A 9-year population-based cohort study. Journal of Hepatology 2015;62:519-25. [DOI: 10.1016/j.jhep.2014.09.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
35 Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, Wu CY. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495-503. [PMID: 25398770 DOI: 10.1136/gutjnl-2014-308163] [Cited by in Crossref: 155] [Cited by in F6Publishing: 132] [Article Influence: 22.1] [Reference Citation Analysis]
36 Vespasiani-Gentilucci U, Galati G, Gallo P, De Vincentis A, Riva E, Picardi A. Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. World J Gastroenterol 2015;21:7412-26. [PMID: 26139987 DOI: 10.3748/wjg.v21.i24.7412] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
37 Cacoub P, Vautier M, Desbois AC, Saadoun D, Younossi Z. Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France. Aliment Pharmacol Ther. 2018;47:123-128. [PMID: 29044584 DOI: 10.1111/apt.14382] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
38 Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN), the Italian Association for the Study of the Liver (AISF), the Italian Society of Infectious and Tropical Disease (SIMIT), the Italian Society of Internal Medicine (SIMI). Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Dig Liver Dis 2018;50:1133-52. [PMID: 30266305 DOI: 10.1016/j.dld.2018.08.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
39 Kao CC, Lin YS, Chu HC, Fang TC, Wu MS, Kang YN. Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis. J Clin Med 2018;7:E314. [PMID: 30274298 DOI: 10.3390/jcm7100314] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
40 Degasperi E, Aghemo A, Colombo M. Treatment of Extrahepatic Manifestations of Hepatitis C Virus. Clin Liver Dis 2017;21:631-43. [PMID: 28689598 DOI: 10.1016/j.cld.2017.03.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
41 Satapathy SK, Joglekar K, Molnar MZ, Ali B, Gonzalez HC, Vanatta JM, Eason JD, Nair SP. Achieving Sustained Virological Response in Liver Transplant Recipients With Hepatitis C Decreases Risk of Decline in Renal Function. Liver Transpl 2018;24:1040-9. [PMID: 29573131 DOI: 10.1002/lt.25059] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
42 Lee YC, Hung SY, Wang HK, Lin CW, Wang HH, Chen SW, Chang MY, Ho LC, Chen YT, Liou HH, Tsai TC, Tseng SH, Wang WM, Lin SH, Chiou YY. Sleep apnea and the risk of chronic kidney disease: a nationwide population-based cohort study. Sleep 2015;38:213-21. [PMID: 25409108 DOI: 10.5665/sleep.4400] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
43 Adinolfi LE, Rinaldi L, Nevola R. Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments? World J Gastroenterol 2018;24:4617-21. [PMID: 30416309 DOI: 10.3748/wjg.v24.i41.4617] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
44 Colombo M, Iavarone M. Role of antiviral treatment for HCC prevention. Best Pract Res Clin Gastroenterol 2014;28:771-81. [PMID: 25260307 DOI: 10.1016/j.bpg.2014.07.017] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
45 Ambrosino P, Lupoli R, Di Minno A, Tarantino L, Spadarella G, Tarantino P, Nasto A, Celentano A, Di Minno MN. The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: A systematic review and meta-analysis. Int J Cardiol. 2016;221:746-754. [PMID: 27428315 DOI: 10.1016/j.ijcard.2016.06.337] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
46 Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine 2014;9:2051-67. [PMID: 24812506 DOI: 10.2147/IJN.S41822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
47 Coppo C, Bonfanti D, Bo S, Giordanino C, Gallo M, Cococcia S, Ciccone G, Smedile A, Ciancio A, Bugianesi E, Fagoonee S, Pellicano R, Rizzetto M, Saracco GM. Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study. Digestive and Liver Disease 2015;47:405-10. [DOI: 10.1016/j.dld.2015.01.157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
48 Chen YC, Li CY, Tsai SJ, Chen YC. Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals. World J Clin Cases 2019;7:1270-81. [PMID: 31236391 DOI: 10.12998/wjcc.v7.i11.1270] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
49 Cacoub P, Commarmond C, Sadoun D, Desbois AC. Hepatitis C Virus Infection and Rheumatic Diseases. Rheumatic Disease Clinics of North America 2017;43:123-32. [DOI: 10.1016/j.rdc.2016.09.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
50 Bruchfeld A, Lindahl K. Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease. Semin Dial 2019;32:135-40. [PMID: 30475421 DOI: 10.1111/sdi.12762] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
51 Al-rabadi L, Box T, Singhania G, Al-marji C, Agarwal A, Hall I, Gordon CE, Tran H. Rationale for treatment of hepatitis C virus infection in end-stage renal disease patients who are not kidney transplant candidates: HCV treatment in ESRD patients. Hemodialysis International 2018;22:S45-52. [DOI: 10.1111/hdi.12656] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Adinolfi LE, Nevola R, Guerrera B, D'Alterio G, Marrone A, Giordano M, Rinaldi L. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018;33:1379-1382. [PMID: 29228501 DOI: 10.1111/jgh.14067] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
53 Pagan J, Ladino M, Roth D. Treating hepatitis C virus in dialysis patients: How, when, and why? Semin Dial 2019;32:152-8. [PMID: 30475415 DOI: 10.1111/sdi.12764] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
54 Babiker A, Jeudy J, Kligerman S, Khambaty M, Shah A, Bagchi S. Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review. J Clin Transl Hepatol. 2017;5:343-362. [PMID: 29226101 DOI: 10.14218/jcth.2017.00021] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
55 Fabrizi F, Messa P. The epidemiology of HCV infection in patients with advanced CKD/ESRD: A global perspective. Semin Dial 2019;32:93-8. [PMID: 30536715 DOI: 10.1111/sdi.12757] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
56 Soriano V, Berenguer J. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients: . Current Opinion in HIV and AIDS 2015;10:309-15. [DOI: 10.1097/coh.0000000000000175] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
57 Chien CH, Lin CL, Hu CC, Chang JJ, Chien RN. Clearance of Hepatitis C Virus Improves Insulin Resistance During and After Peginterferon and Ribavirin Therapy. J Interferon Cytokine Res. 2015;35:981-989. [PMID: 26308911 DOI: 10.1089/jir.2014.0200] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
58 Tong X, Spradling PR. Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004-2011. J Viral Hepat 2015;22:906-13. [PMID: 25894392 DOI: 10.1111/jvh.12414] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
59 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. J Gastroenterol Hepatol. 2017;32:687-694. [PMID: 27577675 DOI: 10.1111/jgh.13589] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
60 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol. 2016;22:9674-9693. [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 54] [Article Influence: 16.3] [Reference Citation Analysis]
61 Ogawa E, Furusyo N, Azuma K, Nakamuta M, Nomura H, Dohmen K, Satoh T, Kawano A, Koyanagi T, Ooho A, Takahashi K, Kato M, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease. Antiviral Res 2018;159:143-52. [PMID: 30300717 DOI: 10.1016/j.antiviral.2018.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
62 Drazilova S, Gazda J, Janicko M, Jarcuska P. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Can J Gastroenterol Hepatol 2018;2018:6150861. [PMID: 30186821 DOI: 10.1155/2018/6150861] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
63 Zhang Z, Rong L, Li YP. Flaviviridae Viruses and Oxidative Stress: Implications for Viral Pathogenesis. Oxid Med Cell Longev 2019;2019:1409582. [PMID: 31531178 DOI: 10.1155/2019/1409582] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
64 Petta S, Adinolfi LE, Fracanzani AL, Rini F, Caldarella R, Calvaruso V, Cammà C, Ciaccio M, Di Marco V, Grimaudo S, Licata A, Marrone A, Nevola R, Pipitone RM, Pinto A, Rinaldi L, Torres D, Tuttolomondo A, Valenti L, Fargion S, Craxì A. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol 2018;69:18-24. [PMID: 29505844 DOI: 10.1016/j.jhep.2018.02.015] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 19.3] [Reference Citation Analysis]
65 Sise ME, Backman ES, Wenger JB, Wood BR, Sax PE, Chung RT, Thadhani R, Kim AY. Short and long-term effects of telaprevir on kidney function in patients with hepatitis C virus infection: a retrospective cohort study. PLoS One. 2015;10:e0124139. [PMID: 25923243 DOI: 10.1371/journal.pone.0124139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Hsu WF, Yu SH, Lin JT, Wu JC, Hou MC, Huang YH, Wu CY, Peng CY. Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study. Gastroenterol Res Pract 2019;2019:1743290. [PMID: 31687012 DOI: 10.1155/2019/1743290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, Goldberg D, Mills PR, Barclay ST, Wilks D, Valerio H, Fox R, Bhattacharyya D, Kennedy N, Morris J, Fraser A, Stanley AJ, Bramley P, Hutchinson SJ. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology. 2015;62:355-364. [PMID: 25716707 DOI: 10.1002/hep.27766] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 12.8] [Reference Citation Analysis]
68 Fabrizi F, Martin P, Messa P. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Kidney Int. 2016;89:988-994. [PMID: 27083277 DOI: 10.1016/j.kint.2016.01.011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 6.6] [Reference Citation Analysis]
69 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver Int 2016;36:817-26. [DOI: 10.1111/liv.13071] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 9.2] [Reference Citation Analysis]
70 Sise ME, McQuaid T, Martin P. Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease. Nephrol Dial Transplant 2021:gfab072. [PMID: 33848334 DOI: 10.1093/ndt/gfab072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
71 Gualerzi A, Bellan M, Smirne C, Tran Minh M, Rigamonti C, Burlone ME, Bonometti R, Bianco S, Re A, Favretto S, Bellomo G, Minisini R, Carnevale Schianca GP, Pirisi M. Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents. PLoS One 2018;13:e0209216. [PMID: 30571711 DOI: 10.1371/journal.pone.0209216] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
72 Bertino G, Ardiri A, Proiti M, Rigano G, Frazzetto E, Demma S, Ruggeri MI, Scuderi L, Malaguarnera G, Bertino N. Chronic hepatitis C: This and the new era of treatment. World J Hepatol. 2016;8:92-106. [PMID: 26807205 DOI: 10.4254/wjh.v8.i2.92] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
73 Mazzitelli M, Torti C, Sabatino J, D'Ascoli GL, Costa C, Pisani V, Raffetti E, De Rosa S, Strazzulla A, Focà A, Liberto MC, Indolfi C; CARDIAC study group. Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients. BMC Infect Dis 2018;18:518. [PMID: 30326844 DOI: 10.1186/s12879-018-3426-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
74 Mohammed AQ, Auckle R, Li HL, Xu SL, Liu L, Zhao DD, Che WL. Pegylated Interferon-α Plus Ribavirin Therapy Improves Left Ventricular Diastolic Dysfunction in Patients With Chronic Hepatitis C Attaining Sustained Virological Response. Am J Med Sci 2018;355:566-72. [PMID: 29891040 DOI: 10.1016/j.amjms.2018.02.001] [Reference Citation Analysis]
75 Sun HL, Yang M, Sait AS, von Drygalski A, Jackson S. Haematuria is not a risk factor of hypertension or renal impairment in patients with haemophilia. Haemophilia 2016;22:549-55. [DOI: 10.1111/hae.12921] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
76 Tran TT, Mehta D, Mensa F, Park C, Bao Y, Sanchez Gonzalez Y. Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials. Infect Dis Ther 2018;7:473-84. [PMID: 30368684 DOI: 10.1007/s40121-018-0218-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
77 Kobayashi N, Iijima H, Tada T, Kumada T, Yoshida M, Aoki T, Nishimura T, Nakano C, Takata R, Yoh K, Ishii A, Takashima T, Sakai Y, Aizawa N, Nishikawa H, Ikeda N, Iwata Y, Enomoto H, Hirota S, Fujimoto J, Nishiguchi S. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Eur J Gastroenterol Hepatol 2018;30:546-51. [PMID: 29494353 DOI: 10.1097/MEG.0000000000001106] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
78 Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV Extrahepatic Manifestations. J Clin Transl Hepatol. 2019;7:172-182. [PMID: 31293918 DOI: 10.14218/jcth.2018.00049] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
79 Boccaccio V, Bruno S. Optimal management of patients with chronic hepatitis C and comorbidities. Liver Int 2015;35:35-43. [DOI: 10.1111/liv.12712] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
80 Negro F. Epidemiology of hepatitis C in Europe. Dig Liver Dis. 2014;46 Suppl 5:S158-S164. [PMID: 25453870 DOI: 10.1016/j.dld.2014.09.023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 7.6] [Reference Citation Analysis]
81 Cacoub P, Buggisch P, Carrión JA, Cooke GS, Zignego AL, Beckerman R, Younossi Z. Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. J Viral Hepat 2018;25:811-7. [DOI: 10.1111/jvh.12881] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
82 Li PK, Bavanandan S, Mohamed R, Szeto CC, Wong VW, Chow KM, Dan YY, Huang CC, Lai CL, Tanwandee T, Teo BW, Wong GL, Yeoh EK, Iseki K, Leung CB, Park HC, Kanjanabuch T, Lu W, Fung J, Jia J, Kanda E, Law MC, Liu H, Loo CK, Mak SK, Lui SL, Tang HL, Wang AY, Yu ML, Cheung M, Jadoul M. 2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. Kidney Int Rep 2020;5:1129-38. [PMID: 32775812 DOI: 10.1016/j.ekir.2020.05.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
83 Puenpatom A, Hull M, McPheeters J, Schwebke K. Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens. Clin Drug Investig 2017;37:687-97. [PMID: 28386819 DOI: 10.1007/s40261-017-0526-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
84 Aoufi-Rabih S, García-Agudo R, Londoño MC, Fraga-Fuentes MD, Barril-Cuadrado G; On behalf on the Spanish Association of the Liver and the Kidney (AEHR). Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney. J Nephrol 2018;31:1-13. [PMID: 29064081 DOI: 10.1007/s40620-017-0446-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
85 Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN)., Italian Association for the Study of the Liver (AISF)., Italian Society of Infectious and Tropical Disease (SIMIT)., Italian Society of Internal Medicine (SIMI). Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). J Nephrol 2018;31:685-712. [PMID: 30255440 DOI: 10.1007/s40620-018-0523-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
86 Roth D, Bloom RD, Molnar MZ, Reese PP, Sawinski D, Sise ME, Terrault NA. KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. Am J Kidney Dis 2020;75:665-83. [PMID: 32279907 DOI: 10.1053/j.ajkd.2019.12.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
87 Su TH, Yang HC, Tseng TC, Chou SW, Lin CH, Liu CH, Liu CJ, Chen CL, Kao JH. Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism. Mov Disord 2019;34:1882-90. [PMID: 31505068 DOI: 10.1002/mds.27848] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
88 Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K. Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease: Ombitasvir/paritaprevir/ritonavir for CHC patients with CKD. Hepatol Res 2018;48:549-55. [DOI: 10.1111/hepr.13058] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
89 Canavesi E, Porzio M, Ruscica M, Rametta R, Macchi C, Pelusi S, Fracanzani AL, Dongiovanni P, Fargion S, Magni P, Valenti L. Increased circulating adiponectin in males with chronic HCV hepatitis. Eur J Intern Med 2015;26:635-9. [PMID: 26293833 DOI: 10.1016/j.ejim.2015.08.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
90 Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2015;60:3801-3813. [PMID: 26195311 DOI: 10.1007/s10620-015-3801-y] [Cited by in Crossref: 76] [Cited by in F6Publishing: 62] [Article Influence: 12.7] [Reference Citation Analysis]
91 Compagnoni S, Bruno EM, Madonia G, Cannizzaro M, Madonia S. Direct antiviral agents in hepatitis C virus related liver disease: Don't count the chickens before they're hatched. World J Gastroenterol 2021;27:2771-83. [PMID: 34135553 DOI: 10.3748/wjg.v27.i21.2771] [Reference Citation Analysis]
92 Colombo M. Interferon-free therapy for hepatitis C: The hurdles amid a golden era. Dig Liver Dis 2015;47:727-33. [PMID: 25937625 DOI: 10.1016/j.dld.2015.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
93 Belli LS, Duvoux C, Berenguer M, Berg T, Coilly A, Colle I, Fagiuoli S, Khoo S, Pageaux GP, Puoti M, Samuel D, Strazzabosco M. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol. 2017;67:585-602. [PMID: 28323126 DOI: 10.1016/j.jhep.2017.03.006] [Cited by in Crossref: 57] [Cited by in F6Publishing: 37] [Article Influence: 14.3] [Reference Citation Analysis]
94 Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN)., Italian Association for the Study of the Liver (AISF)., Italian Society of Infectious and Tropical Disease (SIMIT)., Italian Society of Internal Medicine (SIMI). Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Intern Emerg Med 2018;13:1139-66. [PMID: 30255464 DOI: 10.1007/s11739-018-1940-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Zhang H, Xu H, Wu R, Yu G, Sun H, Lv J, Wang X, Chi X, Gao X, Kong F, Zhang M, Hang L, Jiang J, Pan Y, Niu J. Association of Hepatitis C and B Virus Infection with CKD and Impact of Hepatitis C Treatment on CKD. Sci Rep 2019;9:1910. [PMID: 30760762 DOI: 10.1038/s41598-018-36437-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
96 Stern R, Hametner S, Ramona AZ, Moser S, Karpi A, Laferl H, Stauber RE, Zoller HM, Maieron A, Vogel W, Graziadei I, Gschwantler M, Kozbial K, Freissmuth C, Hofer H, Ferenci P. Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C. Am J Gastroenterol 2016;111:744-5. [PMID: 27151123 DOI: 10.1038/ajg.2016.39] [Reference Citation Analysis]
97 Ampuero J, Romero-Gómez M. Assessing cardiovascular risk in hepatitis C: An unmet need. World J Hepatol. 2015;7:2214-2219. [PMID: 26380047 DOI: 10.4254/wjh.v7.i19.2214] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
98 Park H, Chen C, Wang W, Henry L, Cook RL, Nelson DR. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. Hepatology 2018;67:492-504. [PMID: 28873225 DOI: 10.1002/hep.29505] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
99 Sims OT, Pollio DE, Hong BA, North CS. Racial Disparities in Hepatitis C Treatment Eligibility. Ann Hepatol 2017;16:530-7. [PMID: 28611273 DOI: 10.5604/01.3001.0010.0282] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
100 Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61:S58-68. [PMID: 25443346 DOI: 10.1016/j.jhep.2014.07.012] [Cited by in Crossref: 449] [Cited by in F6Publishing: 390] [Article Influence: 64.1] [Reference Citation Analysis]
101 Bailey AL, Al-Adwan S, Sneij E, Campbell N, Wiisanen ME. Atherosclerotic Cardiovascular Disease in Individuals with Hepatitis C Viral Infection. Curr Cardiol Rep 2021;23:52. [PMID: 33822282 DOI: 10.1007/s11886-021-01475-6] [Reference Citation Analysis]
102 Hsu YH, Hung PH, Muo CH, Tsai WC, Hsu CC, Kao CH. Interferon-Based Treatment of Hepatitis C Virus Infection Reduces All-Cause Mortality in Patients With End-Stage Renal Disease: An 8-Year Nationwide Cohort Study in Taiwan. Medicine (Baltimore). 2015;94:e2113. [PMID: 26632730 DOI: 10.1097/md.0000000000002113] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 3.6] [Reference Citation Analysis]
103 Rossi C, Saeed S, Cox J, Vachon ML, Martel-Laferrière V, Walmsley SL, Cooper C, Gill MJ, Hull M, Moodie EEM, Klein MB; Canadian Co-Infection Cohort Investigators. Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients. AIDS 2018;32:751-9. [PMID: 29369156 DOI: 10.1097/QAD.0000000000001750] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
104 Nahon P, Ganne-Carrié N. Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication. JHEP Rep 2019;1:480-9. [PMID: 32039400 DOI: 10.1016/j.jhepr.2019.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
105 Gastaldi G, Gomes D, Schneiter P, Montet X, Tappy L, Clément S, Negro F. Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients. PLoS One 2019;14:e0217751. [PMID: 31170218 DOI: 10.1371/journal.pone.0217751] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
106 Thuluvath PJ, Savva Y. Mental and physical health-related quality of life in patients with hepatitis C is related to baseline comorbidities and improves only marginally with hepatitis C cure. Clin Transl Gastroenterol 2018;9:149. [PMID: 29691379 DOI: 10.1038/s41424-018-0016-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
107 Mocroft A, Ryom L, Oprea C, Li Q, Rauch A, Boesecke C, Uzdaviniene V, Sedlacek D, Llibre JM, Lacombe K, Nielsen LN, Florence E, Aho I, Chkhartishvili N, Szlavik J, Dragovic G, Leen C, Sambatakou H, Staub T, Laguno M, Elinav H, Tomažič J, Peters L; EuroSIDA study group. Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons. AIDS 2020;34:1485-95. [PMID: 32675562 DOI: 10.1097/QAD.0000000000002570] [Reference Citation Analysis]
108 Fabrizi F, Messa P. Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population? Expert Rev Clin Pharmacol. 2015;8:785-793. [PMID: 26365524 DOI: 10.1586/17512433.2015.1086266] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
109 Revuelto Artigas T, Betriu Bars À, Zaragoza Velasco N, Gómez Arbones X, Vidal Ballester T, Piñol Felis C, Reñé Espinet JM. Antiviral treatment does not improve subclinical atheromatosis in patients with chronic hepatitis caused by hepatitis C virus. Gastroenterol Hepatol 2019;42:362-71. [PMID: 30952463 DOI: 10.1016/j.gastrohep.2019.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Adinolfi LE, Petta S, Fracanzani AL, Coppola C, Narciso V, Nevola R, Rinaldi L, Calvaruso V, Staiano L, Di Marco V, Marrone A, Pafundi PC, Solano A, Lombardi R, Sasso FC, Saturnino M, Rini F, Guerrera B, Troina G, Giordano M, Craxì A. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. Atherosclerosis 2020;296:40-7. [DOI: 10.1016/j.atherosclerosis.2020.01.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 18.0] [Reference Citation Analysis]
111 Cacoub P, Comarmond C. Considering hepatitis C virus infection as a systemic disease. Semin Dial 2019;32:99-107. [PMID: 30549107 DOI: 10.1111/sdi.12758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
112 Cacoub P, Comarmond C, Desbois AC, Saadoun D. Rheumatologic Manifestations of Hepatitis C Virus Infection. Clinics in Liver Disease 2017;21:455-64. [DOI: 10.1016/j.cld.2017.03.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
113 Solis JG, Enciso López ES, Bautista Santos A, Anda Garay JC, Calixto Rodríguez JL, Moreno Alcántar R, Montiel López L. Effect of Direct Antiviral Agents on Atherosclerosis in Patients with Chronic Hepatitis C. Arch Med Res 2021:S0188-4409(21)00115-6. [PMID: 33972118 DOI: 10.1016/j.arcmed.2021.04.009] [Reference Citation Analysis]
114 Morisawa N, Koshima Y, Satoh J, Maruyama Y, Kuriyama S, Yokoo T, Amemiya M. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease. Clin Exp Nephrol 2017;21:818-24. [DOI: 10.1007/s10157-016-1348-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
115 Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S. Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. Am Heart J. 2018;198:4-17. [PMID: 29653647 DOI: 10.1016/j.ahj.2017.10.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
116 Tartof SY, Hsu JW, Wei R, Rubenstein KB, Hu H, Arduino JM, Horberg M, Derose SF, Qian L, Rodriguez CV. Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection. Clin J Am Soc Nephrol. 2018;13:1471-1478. [PMID: 30242027 DOI: 10.2215/cjn.01530218] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
117 Badawi A, Di Giuseppe G, Gupta A, Poirier A, Arora P. Bayesian network modelling study to identify factors influencing the risk of cardiovascular disease in Canadian adults with hepatitis C virus infection. BMJ Open 2020;10:e035867. [PMID: 32371519 DOI: 10.1136/bmjopen-2019-035867] [Reference Citation Analysis]
118 Wu IJ, Chang TS, Hwang SL, Chen MY. Effects of oral hygiene programme and home phone counselling for hepatitis C patients receiving antiviral treatment. J Adv Nurs 2019;75:1010-7. [PMID: 30375059 DOI: 10.1111/jan.13896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
119 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011) 2018;8:91-165. [PMID: 30675443 DOI: 10.1016/j.kisu.2018.06.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 48] [Article Influence: 20.3] [Reference Citation Analysis]
120 Zubkin ML, Chervinko VI, Ovchinnikov YV, Kryukov EV, Kotenko ON. [Chronic HCV infection: An internist's opinion (Part 2)]. Ter Arkh 2016;88:138-48. [PMID: 28635834 DOI: 10.17116/terarkh20168811138-148] [Reference Citation Analysis]
121 Sheu MJ, Liang FW, Li ST, Li CY, Lu TH. Validity of ICD-10-CM Codes Used to Identify Patients with Chronic Hepatitis B and C Virus Infection in Administrative Claims Data from the Taiwan National Health Insurance Outpatient Claims Dataset. Clin Epidemiol 2020;12:185-92. [PMID: 32110110 DOI: 10.2147/CLEP.S236823] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
122 Petruzziello A, Marigliano S, Loquercio G, Cacciapuoti C. Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer. 2016;11:53. [PMID: 27752280 DOI: 10.1186/s13027-016-0099-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 8.2] [Reference Citation Analysis]
123 Hsu Y. Analyzing Taiwan's National Health Insurance Research Database to explicate the allocation of health-care resources. Advances in Digestive Medicine 2015;2:41-3. [DOI: 10.1016/j.aidm.2015.04.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
124 Gaffey AC, Doll SL, Thomasson AM, Venkataraman C, Chen CW, Goldberg LR, Blumberg EA, Acker MA, Stone F, Atluri P. Transplantation of “high-risk” donor hearts: Implications for infection. The Journal of Thoracic and Cardiovascular Surgery 2016;152:213-20. [DOI: 10.1016/j.jtcvs.2015.12.062] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
125 Petta S, Di Marco V, Bruno S, Enea M, Calvaruso V, Boccaccio V, Rossi S, Craxì A, Cammà C. Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. Liver Int. 2016;36:1765-1773. [PMID: 27164508 DOI: 10.1111/liv.13156] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
126 Petta S, Craxi A. Can we prevent and modify cardiometabolic disorders by controlling HCV infection? Gut 2018;67:403-4. [PMID: 28706079 DOI: 10.1136/gutjnl-2017-314505] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
127 Mehta DA, Cohen E, Charafeddine M, Cohen DE, Bao Y, Sanchez Gonzalez Y, Tran TT. Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R+ Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials. Infect Dis Ther. 2017;6:515-529. [PMID: 28939957 DOI: 10.1007/s40121-017-0171-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
128 Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic Morbidity and Mortality of Chronic Hepatitis C. Gastroenterology 2015;149:1345-60. [DOI: 10.1053/j.gastro.2015.08.035] [Cited by in Crossref: 221] [Cited by in F6Publishing: 187] [Article Influence: 36.8] [Reference Citation Analysis]
129 Lee KK, Stelzle D, Bing R, Anwar M, Strachan F, Bashir S, Newby DE, Shah JS, Chung MH, Bloomfield GS, Longenecker CT, Bagchi S, Kottilil S, Blach S, Razavi H, Mills PR, Mills NL, McAllister DA, Shah ASV. Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. Lancet Gastroenterol Hepatol 2019;4:794-804. [PMID: 31377134 DOI: 10.1016/S2468-1253(19)30227-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 14.5] [Reference Citation Analysis]
130 Qi Z, Xia J, Xue X, Liu J, Liu W, Ding S. Targeting viperin improves diet-induced glucose intolerance but not adipose tissue inflammation. Oncotarget 2017;8:101418-36. [PMID: 29254175 DOI: 10.18632/oncotarget.20724] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
131 Lee JJ, Lin MY, Chang JS, Hung CC, Chang JM, Chen HC, Yu ML, Hwang SJ. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One. 2014;9:e100790. [PMID: 24971499 DOI: 10.1371/journal.pone.0100790] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 11.1] [Reference Citation Analysis]
132 Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut. 2018;67:2025-2034. [PMID: 29703790 DOI: 10.1136/gutjnl-2018-316234] [Cited by in Crossref: 70] [Cited by in F6Publishing: 54] [Article Influence: 23.3] [Reference Citation Analysis]
133 Leidner AJ, Chesson HW, Spradling PR, Holmberg SD. Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease. Appl Health Econ Health Policy 2017;15:65-74. [PMID: 27480538 DOI: 10.1007/s40258-016-0261-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
134 Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, Arcaini L, Roccatello D, Antonelli A, Desbois AC, Comarmond C, Gragnani L, Casato M, Lamprecht P, Mangia A, Tzioufas AG, Younossi ZM, Cacoub P; ISG-EHCV. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017;16:523-541. [PMID: 28286108 DOI: 10.1016/j.autrev.2017.03.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 13.0] [Reference Citation Analysis]
135 Pothineni NVK, Subramany S, Kuriakose K, Shirazi LF, Romeo F, Shah PK, Mehta JL. Infections, atherosclerosis, and coronary heart disease. European Heart Journal 2017;38:3195-201. [DOI: 10.1093/eurheartj/ehx362] [Cited by in Crossref: 97] [Cited by in F6Publishing: 61] [Article Influence: 24.3] [Reference Citation Analysis]
136 Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3:3-14. [PMID: 26862398 DOI: 10.1177/2049936115585942] [Cited by in Crossref: 62] [Cited by in F6Publishing: 75] [Article Influence: 12.4] [Reference Citation Analysis]
137 Sevastianos VA, Voulgaris TA, Dourakis SP. Hepatitis C, systemic inflammation and oxidative stress: correlations with metabolic diseases. Expert Review of Gastroenterology & Hepatology 2020;14:27-37. [DOI: 10.1080/17474124.2020.1708191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
138 González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016;22:1421-1432. [PMID: 26819511 DOI: 10.3748/wjg.v22.i4.1421] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 48] [Article Influence: 17.0] [Reference Citation Analysis]
139 Berenguer J, Rodríguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, Mallolas J, Crespo M, Téllez MJ, Quereda C, Sanz J, Barros C, Tural C, Santos I, Pulido F, Guardiola JM, Rubio R, Ortega E, Montes ML, Jusdado JJ, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group. Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2017;66:344-56. [PMID: 28109003 DOI: 10.1002/hep.29071] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
140 van der Meer AJ. Achieving sustained virological response: what’s the impact on further hepatitis C virus-related disease? Expert Review of Gastroenterology & Hepatology 2015;9:559-66. [DOI: 10.1586/17474124.2015.1001366] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
141 Domont F, Cacoub P. Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver Int. 2016;36:621-627. [PMID: 26763484 DOI: 10.1111/liv.13064] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
142 Cacoub P, Comarmond C. New insights into HCV-related rheumatologic disorders: A review. J Adv Res 2017;8:89-97. [PMID: 28149645 DOI: 10.1016/j.jare.2016.07.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
143 Hsieh MH, Bair MJ, Tsai PC, Tseng KC, Lo CC, Chen CY, Kuo HT, Hung CH, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Huang JF, Dai CY, Yu ML, Chuang WL; T-COACH investigators. Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. J Gastroenterol Hepatol 2021;36:2247-54. [PMID: 33624849 DOI: 10.1111/jgh.15469] [Reference Citation Analysis]
144 Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Rajender Reddy K, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol 2019;71:486-97. [PMID: 31096006 DOI: 10.1016/j.jhep.2019.04.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
145 Tsai MC, Lin CY, Hung CH, Lu SN, Tung SY, Chien RN, Lin CL, Wang JH, Chien-Hung C, Chang KC, Hu TH, Sheen IS. Evolution of renal function under direct-acting antivirals treatment for chronic hepatitis C: A real-world experience. J Viral Hepat 2019;26:1404-12. [PMID: 31433885 DOI: 10.1111/jvh.13193] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
146 Craxì A, Perno CF, Viganò M, Ceccherini-silberstein F, Petta S, Aghemo A, Alberti A, Andreone P, Andreoni M, Bonora S, Brunetto MR, Bruno S, Caporaso N, Chirianni A, Ciancio A, Degasperi E, Di Perri G, Fagiuoli S, Ferrari C, Gaeta GB, Pellicelli A, Puoti M, Raimondo G, Taliani G, Villa E, Zignego AL. From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease 2016;48:995-1005. [DOI: 10.1016/j.dld.2016.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
147 Lin MS, Chen TH, Lin WY, Liu CH, Hsieh YY, Chiu WN, Chang CH, Chen MY, Chung CM, Lin YS. Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease - a nationwide cohort study. BMC Gastroenterol 2017;17:99. [PMID: 28814273 DOI: 10.1186/s12876-017-0653-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
148 Rossi C, Jeong D, Wong S, McKee G, Butt ZA, Buxton J, Wong J, Darvishian M, Bartlett S, Samji H, Yu A, Binka M, Alvarez M, Adu PA, Tyndall M, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort Team. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations. J Hepatol 2019;71:1116-25. [PMID: 31433302 DOI: 10.1016/j.jhep.2019.07.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
149 Bedimo R, Abodunde O. Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients. Curr HIV/AIDS Rep. 2016;13:328-339. [PMID: 27595755 DOI: 10.1007/s11904-016-0333-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
150 Azmi AN, Tan SS, Mohamed R. Hepatitis C and kidney disease: An overview and approach to management. World J Hepatol. 2015;7:78-92. [PMID: 25624999 DOI: 10.4254/wjh.v7.i1.78] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
151 Tsai M, Hsu Y, Yu P, Lin C, Kao C. Long-term risk of acute coronary syndrome in hepatitis C virus infected patients without antiviral treatment: A cohort study from an endemic area. International Journal of Cardiology 2015;181:27-9. [DOI: 10.1016/j.ijcard.2014.11.200] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
152 Su X, Zhao X, Deng JL, Li SN, Du X, Dong JZ, Ma CS. Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis. J Viral Hepat 2021;28:664-71. [PMID: 33452699 DOI: 10.1111/jvh.13469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Fabrizi F, Donato FM, Messa P. Association Between Hepatitis C Virus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Ann Hepatol 2018;17:364-91. [PMID: 29735788 DOI: 10.5604/01.3001.0011.7382] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 9.7] [Reference Citation Analysis]
154 Gomaa A, Allam N, Elsharkawy A, El Kassas M, Waked I. Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med 2017;9:17-25. [PMID: 28553150 DOI: 10.2147/HMER.S113681] [Cited by in Crossref: 66] [Cited by in F6Publishing: 22] [Article Influence: 16.5] [Reference Citation Analysis]
155 De Clercq E. Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace: Treatment of hepatitis C accelerating. Rev Med Virol 2015;25:254-67. [DOI: 10.1002/rmv.1842] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
156 Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality? Digestive and Liver Disease 2016;48:105-11. [DOI: 10.1016/j.dld.2015.10.016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
157 Tang L, Marcell L, Kottilil S. Systemic manifestations of hepatitis C infection. Infect Agent Cancer. 2016;11:29. [PMID: 27222662 DOI: 10.1186/s13027-016-0076-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
158 Chang ML, Cheng ML, Chang SW, Tang HY, Chiu CT, Yeh CT, Shiao MS. Recovery of pan-genotypic and genotype-specific amino acid alterations in chronic hepatitis C after viral clearance: transition at the crossroad of metabolism and immunity. Amino Acids. 2017;49:291-302. [PMID: 27830380 DOI: 10.1007/s00726-016-2360-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
159 Russo FP, Zanetto A, Gambato M, Bortoluzzi I, Al Zoairy R, Franceschet E, De Marchi F, Marzi L, Lynch EN, Floreani A, Farinati F, Schaefer B, Burra P, Zoller H, Mega A. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. J Viral Hepat 2020;27:188-94. [PMID: 31596996 DOI: 10.1111/jvh.13215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
160 Ridruejo E, Mendizabal M, Silva MO. Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease: HCV in CKD stages 2-3. Hemodialysis International 2018;22:S97-S103. [DOI: 10.1111/hdi.12651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
161 Fabrizi F, Messa P. Managing hepatitis C therapy failures and chronic kidney disease. Expert Rev Clin Pharmacol 2018;11:1135-42. [PMID: 30309263 DOI: 10.1080/17512433.2018.1534202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
162 Jadoul M, Martin P. Should all dialysis patients with hepatitis C be treated? If so, before or after kidney transplantation? Semin Dial 2017;30:395-7. [DOI: 10.1111/sdi.12640] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
163 Berenguer M, García-Eliz M, Baiguera C, Puoti M. Beyond cure: preventing and managing the complications of end-stage liver disease. Curr Opin HIV AIDS 2015;10:355-60. [PMID: 26248123 DOI: 10.1097/COH.0000000000000184] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
164 Chang ML, Tsou YK, Hu TH, Lin CH, Lin WR, Sung CM, Chen TH, Cheng ML, Chang KC, Chiu CT, Yeh CT, Pang JH, Shiao MS. Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearance. PLoS One. 2014;9:e104783. [PMID: 25122116 DOI: 10.1371/journal.pone.0104783] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
165 Chang ML. Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol. 2016;22:1461-1476. [PMID: 26819514 DOI: 10.3748/wjg.v22.i4.1461] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 53] [Article Influence: 16.0] [Reference Citation Analysis]
166 Broker M, Frager SZ, Patel NS, Lebovics E, Frishman WH. The Inflammatory Relationship Between Hepatitis C Virus With Coronary and Carotid Atherosclerosis. Cardiol Rev 2021;29:178-83. [PMID: 32618587 DOI: 10.1097/CRD.0000000000000314] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
167 Vergniol J, de Lédinghen V. HCV: Fibrosis Progression. Curr Hepatology Rep 2014;13:265-72. [DOI: 10.1007/s11901-014-0247-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
168 Gastaldi G, Goossens N, Clément S, Negro F. Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review. J Adv Res 2017;8:149-59. [PMID: 28149650 DOI: 10.1016/j.jare.2016.11.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
169 Negro F. Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. Journal of Hepatology 2014;61:S69-78. [DOI: 10.1016/j.jhep.2014.08.003] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 13.6] [Reference Citation Analysis]